Literature DB >> 17761123

Functional heartburn, nonerosive reflux disease, and reflux esophagitis are all distinct conditions--a debate: con.

Lucía C Fry1, Klaus Mönkemüller, Peter Malfertheiner.   

Abstract

Gastroesophageal reflux disease (GERD) is currently defined as a condition that develops when the reflux of stomach contents causes recurrent symptoms and/or complications. The clinical presentation of GERD has been recognized to be much broader than before, when the typical symptoms of heartburn and acid regurgitation were considered as the main clinical presentation. However, now it is recognized that GERD can present with various other mainly extraesophageal symptoms, abdominal pain, and even sleep disturbance. Moreover, there is an important overlap with functional gastrointestinal disorders such as functional dyspepsia and irritable bowel syndrome. The morphologic spectrum of esophageal involvement in GERD encompasses erosive (erosive reflux disease ), Barrett's esophagus (BE), and nonerosive reflux disease (NERD). However, there is still no consensus on whether GERD represents one disease that can progress from NERD to ERD and BE, or whether it is a spectrum of different conditions with its own clinical, pathophysiologic, and endoscopic characteristics. Recently published data suggest that mild erosive esophagitis behaves in a way similar to NERD and that there is considerable movement between these categories. But follow-up data also show that after 2 years, some patients with NERD or GERD Los Angeles A or B went on to develop severe GERD or even BE. A practical approach is to categorize patients with reflux symptoms into "functional heartburn" (ie, reflux symptoms and negative endoscopy and absent objective evidence of acid reflux into the esophagus), NERD (negative endoscopy but positive documentation of acid reflux into the esophagus), and ERD (erosions documented endoscopically). In conclusion, it appears that GERD is a disease with a spectrum of clinical and endoscopic manifestations, with characteristics that make it a continuum and not a categorical condition with separate entities. It is difficult to clearly delineate the spectrum of GERD based on the clinical, endoscopic, and pathophysiologic characteristics, but therapeutic trials and follow-up studies suggest that GERD is not composed of different conditions.

Entities:  

Year:  2007        PMID: 17761123     DOI: 10.1007/s11938-007-0073-4

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  29 in total

1.  Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota.

Authors:  G R Locke; N J Talley; S L Fett; A R Zinsmeister; L J Melton
Journal:  Gastroenterology       Date:  1997-05       Impact factor: 22.682

2.  Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study.

Authors:  P Malfertheiner; T Lind; S Willich; M Vieth; D Jaspersen; J Labenz; W Meyer-Sabellek; O Junghard; M Stolte
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

3.  Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams.

Authors:  Kenneth R Devault; John F Johanson; David A Johnson; Sherry Liu; Mark B Sostek
Journal:  Clin Gastroenterol Hepatol       Date:  2006-05-06       Impact factor: 11.382

4.  Non-erosive reflux disease (NERD)--acid reflux and symptom patterns.

Authors:  S D Martinez; I B Malagon; H S Garewal; H Cui; R Fass
Journal:  Aliment Pharmacol Ther       Date:  2003-02-15       Impact factor: 8.171

5.  On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis--a placebo-controlled randomized trial.

Authors:  T Lind; T Havelund; L Lundell; H Glise; K Lauritsen; S A Pedersen; O Anker-Hansen; A Stubberöd; G Eriksson; R Carlsson; O Junghard
Journal:  Aliment Pharmacol Ther       Date:  1999-07       Impact factor: 8.171

6.  Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis.

Authors:  Donald O Castell; Peter J Kahrilas; Joel E Richter; Nimish B Vakil; David A Johnson; Seth Zuckerman; Wendy Skammer; Jeffrey G Levine
Journal:  Am J Gastroenterol       Date:  2002-03       Impact factor: 10.864

7.  Heartburn refractory to proton-pump inhibitors.

Authors:  Apurva Trivedi; John D Long
Journal:  Curr Treat Options Gastroenterol       Date:  2007-02

8.  Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study.

Authors:  H H Tsai; R Chapman; A Shepherd; D McKeith; M Anderson; D Vearer; S Duggan; J P Rosen
Journal:  Aliment Pharmacol Ther       Date:  2004-09-15       Impact factor: 8.171

9.  Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice.

Authors:  T L Venables; R D Newland; A C Patel; J Hole; C Wilcock; M L Turbitt
Journal:  Scand J Gastroenterol       Date:  1997-10       Impact factor: 2.423

10.  The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole.

Authors:  D Armstrong; N J Talley; K Lauritsen; B Moum; T Lind; H Tunturi-Hihnala; T Venables; J Green; M A Bigard; J Mössner; O Junghard
Journal:  Aliment Pharmacol Ther       Date:  2004-08-15       Impact factor: 8.171

View more
  1 in total

1.  Role of tight junction proteins in gastroesophageal reflux disease.

Authors:  Klaus Mönkemüller; Thomas Wex; Doerthe Kuester; Lucia C Fry; Arne Kandulski; Siegfried Kropf; Albert Roessner; Peter Malfertheiner
Journal:  BMC Gastroenterol       Date:  2012-09-20       Impact factor: 3.067

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.